Slingshot members are tracking this event:

Celldex's (CLDX) Phase 2b METRIC Study glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers Discontinued

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The Company's randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda (capecitabine) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival (PFS) as assessed by an independent, central reading of patient scans (Hazard ratio = 0.95; median PFS: glembatumumab vedotin 2.9 months vs. Xeloda 2.8 months; p=0.76). There was no significant advantage for glembatumumab vedotin in key secondary endpoints, including overall response rate, duration of response and overall survival. The glembatumumab vedotin safety profile was consistent with prior experience.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 16, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Metric Study, Glembatumumab Vedotin, Xeloda, (capecitabine)